No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
RXRX241213C4000
- 0.00
- 0.000.00%
15min DelayClose Dec 11 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover1537.67%IV-47.16%PremiumDec 13, 2024Expiry Date3.57Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8732Delta0.0281Gamma1.74Leverage Ratio-0.5947Theta0.0001Rho1.52Eff Leverage0.0010Vega
Intraday
- 5D
- Daily
No Data
News
Hold Rating for Recursion Pharmaceuticals Amid Early Efficacy Signals and Financial Concerns
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings